ENTITY

Oryzon Genomics (ORY SM)

53
Analysis
Health CareSpain
Oryzon Genomics, SA is a clinical stage biopharmaceutical company that develops epigenetics-based therapeutics.
more
Refresh
bullishOryzon Genomics
26 Jul 2022 20:59Issuer-paid

Oryzon Genomics - Preclinical collaboration in orphan disease

Oryzon Genomics has announced that it is has entered into a partnership with the Charcot-Marie-Tooth Research Foundation (CMTRF). The collaboration...

Share
bullishOryzon Genomics
25 Jul 2022 20:30Issuer-paid

Oryzon Genomics - Costs up but company remains well funded

Oryzon Genomics has reported results for H122 and highlighted the progress of key assets iadademstat and vafidemstat during the period. It reported...

Share
bullishOryzon Genomics
19 Jul 2022 17:54Issuer-paid

Oryzon Genomics - CRADA win to provide a halo effect

Oryzon has been awarded a Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute (NCI) to develop its lead...

Share
bullishOryzon Genomics
06 Jul 2022 16:14Issuer-paid

Oryzon Genomics - Key milestones and extended cash runway

Oryzon is progressing with its lead assets, iadademstat and vafidemstat, in the clinic. The ALICE study continues to generate positive readouts in...

Share
bullishOryzon Genomics
10 Jun 2022 16:28Issuer-paid

Oryzon Genomics - Continued positive responses in ALICE trial

Oryzon presented a 42-month update of its ongoing Phase IIa ALICE trial for the treatment of acute myeloid leukaemia (AML) in newly diagnosed...

Share
x